Department of Molecular Microbiology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Br J Cancer. 2023 Oct;129(8):1251-1260. doi: 10.1038/s41416-023-02408-6. Epub 2023 Sep 15.
Although genome duplication, or polyploidization, is believed to drive cancer evolution and affect tumor features, its significance in hepatocellular carcinoma (HCC) is unclear. We aimed to determine the characteristics of polyploid HCCs by evaluating chromosome duplication and to discover surrogate markers to discriminate polyploid HCCs.
The ploidy in human HCC was assessed by fluorescence in situ hybridization for multiple chromosomes. Clinicopathological and expression features were compared between polyploid and near-diploid HCCs. Markers indicating polyploid HCC were explored by transcriptome analysis of cultured HCC cells.
Polyploidy was detected in 36% (20/56) of HCCs and discriminated an aggressive subset of HCC that typically showed high serum alpha-fetoprotein, poor differentiation, and poor prognosis compared to near-diploid HCCs. Molecular subtyping revealed that polyploid HCCs highly expressed alpha-fetoprotein but did not necessarily show progenitor features. Histological examination revealed abundant polyploid giant cancer cells (PGCCs) with a distinct appearance and frequent macrotrabecular-massive architecture in polyploid HCCs. Notably, the abundance of PGCCs and overexpression of ubiquitin-conjugating enzymes 2C indicated polyploidy in HCC and efficiently predicted poor prognosis in combination.
Histological diagnosis of polyploidy using surrogate markers discriminates an aggressive subset of HCC, apart from known HCC subgroups, and predict poor prognosis in HCC.
尽管人们认为基因组加倍或多倍体化会推动癌症进化并影响肿瘤特征,但它在肝细胞癌(HCC)中的意义尚不清楚。我们旨在通过评估染色体加倍来确定多倍体 HCC 的特征,并发现用于区分多倍体 HCC 的替代标志物。
通过多重染色体荧光原位杂交评估人 HCC 的ploidy。比较多倍体和近二倍体 HCC 之间的临床病理和表达特征。通过培养的 HCC 细胞的转录组分析探索指示多倍体 HCC 的标志物。
在 36%(20/56)的 HCC 中检测到多倍体,并区分出侵袭性亚组 HCC,与近二倍体 HCC 相比,其通常表现出高血清甲胎蛋白、低分化和预后不良。分子亚分型显示,多倍体 HCC 高度表达甲胎蛋白,但不一定表现出祖细胞特征。组织学检查显示多倍体 HCC 中存在大量多倍体巨癌细胞(PGCC),其外观明显,且常出现大小梁-块状结构。值得注意的是,PGCC 的丰度和泛素结合酶 2C 的过表达指示 HCC 的多倍体,并结合有效地预测了不良预后。
使用替代标志物进行组织学诊断多倍体可区分 HCC 的侵袭性亚组,与已知的 HCC 亚组不同,并预测 HCC 的不良预后。